<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39325826</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>08</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>10</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1553-7374</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Sep</Month></PubDate></JournalIssue><Title>PLoS pathogens</Title><ISOAbbreviation>PLoS Pathog</ISOAbbreviation></Journal><ArticleTitle>Structure-guided in vitro evolution of nanobodies targeting new viral variants.</ArticleTitle><Pagination><StartPage>e1012600</StartPage><MedlinePgn>e1012600</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e1012600</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.ppat.1012600</ELocationID><Abstract><AbstractText>A major challenge in antiviral antibody therapy is keeping up with the rapid evolution of viruses. Our research shows that nanobodies - single-domain antibodies derived from camelids - can be rapidly re-engineered to combat new viral strains through structure-guided in vitro evolution. Specifically, for viral mutations occurring at nanobody-binding sites, we introduce randomized amino acid sequences into nanobody residues near these mutations. We then select nanobody variants that effectively bind to the mutated viral target from a phage display library. As a proof of concept, we used this approach to adapt Nanosota-3, a nanobody originally identified to target the receptor-binding domain (RBD) of early Omicron subvariants, making it highly effective against recent Omicron subvariants. Remarkably, this adaptation process can be completed in less than two weeks, allowing drug development to keep pace with viral evolution and provide timely protection to humans.</AbstractText><CopyrightInformation>Copyright: © 2024 Ye et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ye</LastName><ForeName>Gang</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, University of Minnesota Medical School, Minneapolis, Minnesota, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Emerging Viruses, University of Minnesota, Minneapolis, Minnesota, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bu</LastName><ForeName>Fan</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, University of Minnesota Medical School, Minneapolis, Minnesota, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Emerging Viruses, University of Minnesota, Minneapolis, Minnesota, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pan</LastName><ForeName>Ruangang</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, University of Iowa, Iowa City, Iowa, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mendoza</LastName><ForeName>Alise</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, University of Minnesota Medical School, Minneapolis, Minnesota, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Emerging Viruses, University of Minnesota, Minneapolis, Minnesota, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Ge</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Hormel Institute, University of Minnesota, Austin, Minnesota, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spiller</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wadzinski</LastName><ForeName>Brian E</ForeName><Initials>BE</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Du</LastName><ForeName>Lanying</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Institute for Biomedical Sciences, Georgia State University, Atlanta, Georgia, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perlman</LastName><ForeName>Stanley</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, University of Iowa, Iowa City, Iowa, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Bin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Hormel Institute, University of Minnesota, Austin, Minnesota, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Fang</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-1958-366X</Identifier><AffiliationInfo><Affiliation>Department of Pharmacology, University of Minnesota Medical School, Minneapolis, Minnesota, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Emerging Viruses, University of Minnesota, Minneapolis, Minnesota, United States of America.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AI089728</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AI157975</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AI171954</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS Pathog</MedlineTA><NlmUniqueID>101238921</NlmUniqueID><ISSNLinking>1553-7366</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061905">Single-Domain Antibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Organism" UI="C000711908">SARS-CoV-2 variants</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D061905" MajorTopicYN="Y">Single-Domain Antibodies</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="N">Spike Glycoprotein, Coronavirus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The University of Minnesota has filed patents on Nanosota-3 with F.L, G.Y., F.B., and B.L. as inventors. B.E.W. and B.S. are co-founders of Turkey Creek Biotechnology.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>10</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>8</Day><Hour>22</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>26</Day><Hour>19</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>26</Day><Hour>13</Hour><Minute>53</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39325826</ArticleId><ArticleId IdType="pmc">PMC11460708</ArticleId><ArticleId IdType="doi">10.1371/journal.ppat.1012600</ArticleId><ArticleId IdType="pii">PPATHOGENS-D-24-00980</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Xiong D, Zhao X, Luo S, Cong Y, Zhang JZH, Duan L. Immune Escape Mechanisms of SARS-CoV-2 Delta and Omicron Variants against Two Monoclonal Antibodies That Received Emergency Use Authorization. J Phys Chem Lett. 2022;13(26):6064–73. Epub 20220627. doi: 10.1021/acs.jpclett.2c00912 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jpclett.2c00912</ArticleId><ArticleId IdType="pubmed">35758899</ArticleId></ArticleIdList></Reference><Reference><Citation>Planas D, Bruel T, Staropoli I, Guivel-Benhassine F, Porrot F, Maes P, et al.. Resistance of Omicron subvariants BA.2.75.2, BA.4.6, and BQ.1.1 to neutralizing antibodies. Nature communications. 2023;14(1):824. Epub 20230214. doi: 10.1038/s41467-023-36561-6 ; PubMed Central PMCID: PMC9926440.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-36561-6</ArticleId><ArticleId IdType="pmc">PMC9926440</ArticleId><ArticleId IdType="pubmed">36788246</ArticleId></ArticleIdList></Reference><Reference><Citation>Arora P, Kempf A, Nehlmeier I, Schulz SR, Jäck HM, Pöhlmann S, Hoffmann M. Omicron sublineage BQ.1.1 resistance to monoclonal antibodies. Lancet Infect Dis. 2023;23(1):22–3. Epub 20221118. doi: 10.1016/S1473-3099(22)00733-2 ; PubMed Central PMCID: PMC9707647.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(22)00733-2</ArticleId><ArticleId IdType="pmc">PMC9707647</ArticleId><ArticleId IdType="pubmed">36410372</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann M, Krüger N, Schulz S, Cossmann A, Rocha C, Kempf A, et al.. The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic. Cell. 2022;185(3):447–56.e11. Epub 20211224. doi: 10.1016/j.cell.2021.12.032 ; PubMed Central PMCID: PMC8702401.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.12.032</ArticleId><ArticleId IdType="pmc">PMC8702401</ArticleId><ArticleId IdType="pubmed">35026151</ArticleId></ArticleIdList></Reference><Reference><Citation>Tada T, Zhou H, Dcosta BM, Samanovic MI, Chivukula V, Herati RS, et al.. Increased resistance of SARS-CoV-2 Omicron variant to neutralization by vaccine-elicited and therapeutic antibodies. EBioMedicine. 2022;78:103944. doi: 10.1016/j.ebiom.2022.103944 ; PubMed Central PMCID: PMC9021600.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2022.103944</ArticleId><ArticleId IdType="pmc">PMC9021600</ArticleId><ArticleId IdType="pubmed">35465948</ArticleId></ArticleIdList></Reference><Reference><Citation>Uraki R, Kiso M, Imai M, Yamayoshi S, Ito M, Fujisaki S, et al.. Therapeutic efficacy of monoclonal antibodies and antivirals against SARS-CoV-2 Omicron BA.1 in Syrian hamsters. Nature microbiology. 2022;7(8):1252–8. Epub 20220615. doi: 10.1038/s41564-022-01170-4 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41564-022-01170-4</ArticleId><ArticleId IdType="pubmed">35705860</ArticleId></ArticleIdList></Reference><Reference><Citation>Li F. Structure, Function, and Evolution of Coronavirus Spike Proteins. Annual review of virology. 2016;3(1):237–61. Epub 2016/09/01. doi: 10.1146/annurev-virology-110615-042301 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-virology-110615-042301</ArticleId><ArticleId IdType="pmc">PMC5457962</ArticleId><ArticleId IdType="pubmed">27578435</ArticleId></ArticleIdList></Reference><Reference><Citation>Du LY, He YX, Zhou YS, Liu SW, Zheng BJ, Jiang SB. The spike protein of SARS-CoV—a target for vaccine and therapeutic development. Nature Reviews Microbiology. 2009;7(3):226–36. doi: 10.1038/nrmicro2090 ISI:000263361000014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrmicro2090</ArticleId><ArticleId IdType="pmc">PMC2750777</ArticleId><ArticleId IdType="pubmed">19198616</ArticleId></ArticleIdList></Reference><Reference><Citation>Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus. Journal of virology. 2020;94(7): doi: 10.1128/JVI.00127-20</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00127-20</ArticleId><ArticleId IdType="pmc">PMC7081895</ArticleId><ArticleId IdType="pubmed">31996437</ArticleId></ArticleIdList></Reference><Reference><Citation>Bajpai P, Singh V, Chandele A, Kumar S. Broadly Neutralizing Antibodies to SARS-CoV-2 Provide Novel Insights Into the Neutralization of Variants and Other Human Coronaviruses. Front Cell Infect Microbiol. 2022;12:928279. Epub 20220616. doi: 10.3389/fcimb.2022.928279 ; PubMed Central PMCID: PMC9245455.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2022.928279</ArticleId><ArticleId IdType="pmc">PMC9245455</ArticleId><ArticleId IdType="pubmed">35782120</ArticleId></ArticleIdList></Reference><Reference><Citation>Hao A, Song W, Li C, Zhang X, Tu C, Wang X, et al.. Defining a highly conserved cryptic epitope for antibody recognition of SARS-CoV-2 variants. Signal transduction and targeted therapy. 2023;8(1):269. Epub 20230708. doi: 10.1038/s41392-023-01534-0 ; PubMed Central PMCID: PMC10329685.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-023-01534-0</ArticleId><ArticleId IdType="pmc">PMC10329685</ArticleId><ArticleId IdType="pubmed">37422451</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao F, Zai X, Zhang Z, Xu J, Chen W. Challenges and developments in universal vaccine design against SARS-CoV-2 variants. NPJ vaccines. 2022;7(1):167. Epub 20221219. doi: 10.1038/s41541-022-00597-4 ; PubMed Central PMCID: PMC9761649.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41541-022-00597-4</ArticleId><ArticleId IdType="pmc">PMC9761649</ArticleId><ArticleId IdType="pubmed">36535982</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang X, Kon E, Han X, Zhang X, Kong N, Mitchell MJ, et al.. Nanotechnology-based strategies against SARS-CoV-2 variants. Nat Nanotechnol. 2022;17(10):1027–37. Epub 20220818. doi: 10.1038/s41565-022-01174-5 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41565-022-01174-5</ArticleId><ArticleId IdType="pubmed">35982317</ArticleId></ArticleIdList></Reference><Reference><Citation>Könning D, Zielonka S, Grzeschik J, Empting M, Valldorf B, Krah S, et al.. Camelid and shark single domain antibodies: structural features and therapeutic potential. Curr Opin Struct Biol. 2017;45:10–6. Epub 2016/11/20. doi: 10.1016/j.sbi.2016.10.019 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.sbi.2016.10.019</ArticleId><ArticleId IdType="pubmed">27865111</ArticleId></ArticleIdList></Reference><Reference><Citation>De Meyer T, Muyldermans S, Depicker A. Nanobody-based products as research and diagnostic tools. Trends Biotechnol. 2014;32(5):263–70. Epub 2014/04/05. doi: 10.1016/j.tibtech.2014.03.001 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tibtech.2014.03.001</ArticleId><ArticleId IdType="pubmed">24698358</ArticleId></ArticleIdList></Reference><Reference><Citation>Du L, Yang Y, Zhang X, Li F. Recent advances in nanotechnology-based COVID-19 vaccines and therapeutic antibodies. Nanoscale. 2022;14(4):1054–74. Epub 20220127. doi: 10.1039/d1nr03831a ; PubMed Central PMCID: PMC8863106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/d1nr03831a</ArticleId><ArticleId IdType="pmc">PMC8863106</ArticleId><ArticleId IdType="pubmed">35018939</ArticleId></ArticleIdList></Reference><Reference><Citation>Muyldermans S. Nanobodies: natural single-domain antibodies. Annu Rev Biochem. 2013;82:775–97. Epub 2013/03/19. doi: 10.1146/annurev-biochem-063011-092449 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-biochem-063011-092449</ArticleId><ArticleId IdType="pubmed">23495938</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanlandschoot P, Stortelers C, Beirnaert E, Ibañez LI, Schepens B, Depla E, Saelens X. Nanobodies: new ammunition to battle viruses. Antiviral Res. 2011;92(3):389–407. Epub 20110910. doi: 10.1016/j.antiviral.2011.09.002 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2011.09.002</ArticleId><ArticleId IdType="pubmed">21939690</ArticleId></ArticleIdList></Reference><Reference><Citation>Steeland S, Vandenbroucke RE, Libert C. Nanobodies as therapeutics: big opportunities for small antibodies. Drug discovery today. 2016;21(7):1076–113. Epub 2016/04/16. doi: 10.1016/j.drudis.2016.04.003 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.drudis.2016.04.003</ArticleId><ArticleId IdType="pubmed">27080147</ArticleId></ArticleIdList></Reference><Reference><Citation>Arbabi Ghahroudi M, Desmyter A, Wyns L, Hamers R, Muyldermans S. Selection and identification of single domain antibody fragments from camel heavy-chain antibodies. FEBS Lett. 1997;414(3):521–6. doi: 10.1016/s0014-5793(97)01062-4 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0014-5793(97)01062-4</ArticleId><ArticleId IdType="pubmed">9323027</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye G, Gallant J, Zheng J, Massey C, Shi K, Tai W, et al.. The development of Nanosota-1 as anti-SARS-CoV-2 nanobody drug candidates. eLife. 2021;10:e64815. doi: 10.7554/eLife.64815</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.64815</ArticleId><ArticleId IdType="pmc">PMC8354634</ArticleId><ArticleId IdType="pubmed">34338634</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye G, Pan R, Bu F, Zheng J, Mendoza A, Wen W, et al.. Discovery of Nanosota-2,-3, and-4 as super potent and broad-spectrum therapeutic nanobody candidates against COVID-19. Journal of Virology. 2023:e01448–23. doi: 10.1128/jvi.01448-23</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.01448-23</ArticleId><ArticleId IdType="pmc">PMC10688364</ArticleId><ArticleId IdType="pubmed">37855638</ArticleId></ArticleIdList></Reference><Reference><Citation>Geng Q, Wan Y, Hsueh F-C, Shang J, Ye G, Bu F, et al.. Lys417 acts as a molecular switch that regulates the conformation of SARS-CoV-2 spike protein. eLife. 2023;12:e74060. doi: 10.7554/eLife.74060</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.74060</ArticleId><ArticleId IdType="pmc">PMC10695562</ArticleId><ArticleId IdType="pubmed">37991488</ArticleId></ArticleIdList></Reference><Reference><Citation>Shang J, Wan Y, Luo C, Ye G, Geng Q, Auerbach A, Li F. Cell entry mechanisms of SARS-CoV-2. Proceedings of the National Academy of Sciences. 2020;117(21):11727–34. doi: 10.1073/pnas.2003138117</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2003138117</ArticleId><ArticleId IdType="pmc">PMC7260975</ArticleId><ArticleId IdType="pubmed">32376634</ArticleId></ArticleIdList></Reference><Reference><Citation>Kinoshita S, Nakakido M, Mori C, Kuroda D, Caaveiro JMM, Tsumoto K. Molecular basis for thermal stability and affinity in a VHH: Contribution of the framework region and its influence in the conformation of the CDR3. Protein science: a publication of the Protein Society. 2022;31(11):e4450. doi: 10.1002/pro.4450 ; PubMed Central PMCID: PMC9601775.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pro.4450</ArticleId><ArticleId IdType="pmc">PMC9601775</ArticleId><ArticleId IdType="pubmed">36153698</ArticleId></ArticleIdList></Reference><Reference><Citation>Valdés-Tresanco MS, Valdés-Tresanco ME, Molina-Abad E, Moreno E. NbThermo: a new thermostability database for nanobodies. Database (Oxford). 2023;2023. doi: 10.1093/database/baad021 ; PubMed Central PMCID: PMC10091358.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/database/baad021</ArticleId><ArticleId IdType="pmc">PMC10091358</ArticleId><ArticleId IdType="pubmed">37042467</ArticleId></ArticleIdList></Reference><Reference><Citation>Atwell S, Ultsch M, De Vos AM, Wells JA. Structural plasticity in a remodeled protein-protein interface. Science. 1997;278(5340):1125–8. doi: 10.1126/science.278.5340.1125 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.278.5340.1125</ArticleId><ArticleId IdType="pubmed">9353194</ArticleId></ArticleIdList></Reference><Reference><Citation>Matthews JM. Plasticity at Protein–Protein Interaction Interfaces. In: Roberts GCK, editor. Encyclopedia of Biophysics. Berlin, Heidelberg: Springer Berlin Heidelberg; 2013. p. 1886–8.</Citation></Reference><Reference><Citation>Koide A, Koide S. Affinity maturation of single-domain antibodies by yeast surface display. Methods in molecular biology (Clifton, NJ). 2012;911:431–43. doi: 10.1007/978-1-61779-968-6_26 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-61779-968-6_26</ArticleId><ArticleId IdType="pubmed">22886267</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoof M, Faust B, Saunders RA, Sangwan S, Rezelj V, Hoppe N, et al.. An ultrapotent synthetic nanobody neutralizes SARS-CoV-2 by stabilizing inactive Spike. Science. 2020;370(6523):1473–9. Epub 2020/11/07. doi: 10.1126/science.abe3255 ; PubMed Central PMCID: PMC7857409.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abe3255</ArticleId><ArticleId IdType="pmc">PMC7857409</ArticleId><ArticleId IdType="pubmed">33154106</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipovsek D, Lippow SM, Hackel BJ, Gregson MW, Cheng P, Kapila A, Wittrup KD. Evolution of an interloop disulfide bond in high-affinity antibody mimics based on fibronectin type III domain and selected by yeast surface display: molecular convergence with single-domain camelid and shark antibodies. J Mol Biol. 2007;368(4):1024–41. Epub 20070222. doi: 10.1016/j.jmb.2007.02.029 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmb.2007.02.029</ArticleId><ArticleId IdType="pubmed">17382960</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobs JL, Haidar G, Mellors JW. COVID-19: Challenges of Viral Variants. Annu Rev Med. 2023;74:31–53. Epub 20220718. doi: 10.1146/annurev-med-042921-020956 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-med-042921-020956</ArticleId><ArticleId IdType="pubmed">35850493</ArticleId></ArticleIdList></Reference><Reference><Citation>Vasireddy D, Vanaparthy R, Mohan G, Malayala SV, Atluri P. Review of COVID-19 Variants and COVID-19 Vaccine Efficacy: What the Clinician Should Know? J Clin Med Res. 2021;13(6):317–25. Epub 20210625. doi: 10.14740/jocmr4518 ; PubMed Central PMCID: PMC8256910.</Citation><ArticleIdList><ArticleId IdType="doi">10.14740/jocmr4518</ArticleId><ArticleId IdType="pmc">PMC8256910</ArticleId><ArticleId IdType="pubmed">34267839</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong W, Parkkila S, Wu X, Aspatwar A. SARS-CoV-2 variants and COVID-19 vaccines: Current challenges and future strategies. Int Rev Immunol. 2023;42(6):393–414. Epub 20220528. doi: 10.1080/08830185.2022.2079642 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/08830185.2022.2079642</ArticleId><ArticleId IdType="pubmed">35635216</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y, Li F, Du L. Therapeutic nanobodies against SARS-CoV-2 and other pathogenic human coronaviruses. J Nanobiotechnology. 2024;22(1):304. Epub 20240531. doi: 10.1186/s12951-024-02573-7 ; PubMed Central PMCID: PMC11140877.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12951-024-02573-7</ArticleId><ArticleId IdType="pmc">PMC11140877</ArticleId><ArticleId IdType="pubmed">38822339</ArticleId></ArticleIdList></Reference><Reference><Citation>Geng Q, Tai W, Baxter VK, Shi J, Wan Y, Zhang X, et al.. Novel virus-like nanoparticle vaccine effectively protects animal model from SARS-CoV-2 infection. PLoS Pathog. 2021;17(9):e1009897. doi: 10.1371/journal.ppat.1009897</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1009897</ArticleId><ArticleId IdType="pmc">PMC8448314</ArticleId><ArticleId IdType="pubmed">34492082</ArticleId></ArticleIdList></Reference><Reference><Citation>Punjani A, Rubinstein JL, Fleet DJ, Brubaker MA. cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination. Nature methods. 2017;14(3):290–6. Epub 2017/02/07. doi: 10.1038/nmeth.4169 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.4169</ArticleId><ArticleId IdType="pubmed">28165473</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubinstein JL, Brubaker MA. Alignment of cryo-EM movies of individual particles by optimization of image translations. Journal of structural biology. 2015;192(2):188–95. Epub 2015/08/25. doi: 10.1016/j.jsb.2015.08.007 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsb.2015.08.007</ArticleId><ArticleId IdType="pubmed">26296328</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohou A, Grigorieff N. CTFFIND4: Fast and accurate defocus estimation from electron micrographs. Journal of structural biology. 2015;192(2):216–21. Epub 2015/08/19. doi: 10.1016/j.jsb.2015.08.008 ; PubMed Central PMCID: PMC6760662.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsb.2015.08.008</ArticleId><ArticleId IdType="pmc">PMC6760662</ArticleId><ArticleId IdType="pubmed">26278980</ArticleId></ArticleIdList></Reference><Reference><Citation>Zivanov J, Nakane T, Scheres SHW. Estimation of high-order aberrations and anisotropic magnification from cryo-EM data sets in RELION-3.1. IUCrJ. 2020;7(Pt 2):253–67. Epub 2020/03/10. doi: 10.1107/S2052252520000081 ; PubMed Central PMCID: PMC7055373.</Citation><ArticleIdList><ArticleId IdType="doi">10.1107/S2052252520000081</ArticleId><ArticleId IdType="pmc">PMC7055373</ArticleId><ArticleId IdType="pubmed">32148853</ArticleId></ArticleIdList></Reference><Reference><Citation>Emsley P, Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallographica Section D-Biological Crystallography. 2004;60:2126–32. doi: 10.1107/S0907444904019158 WOS:000225360500002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1107/S0907444904019158</ArticleId><ArticleId IdType="pubmed">15572765</ArticleId></ArticleIdList></Reference><Reference><Citation>Adams PD, Afonine PV, Bunkoczi G, Chen VB, Davis IW, Echols N, et al.. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallographica Section D-Biological Crystallography. 2010;66:213–21. doi: 10.1107/S0907444909052925 ISI:000273820800013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1107/S0907444909052925</ArticleId><ArticleId IdType="pmc">PMC2815670</ArticleId><ArticleId IdType="pubmed">20124702</ArticleId></ArticleIdList></Reference><Reference><Citation>Goddard TD, Huang CC, Meng EC, Pettersen EF, Couch GS, Morris JH, Ferrin TE. UCSF ChimeraX: Meeting modern challenges in visualization and analysis. Protein science: a publication of the Protein Society. 2018;27(1):14–25. Epub 2017/07/16. doi: 10.1002/pro.3235 ; PubMed Central PMCID: PMC5734306.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pro.3235</ArticleId><ArticleId IdType="pmc">PMC5734306</ArticleId><ArticleId IdType="pubmed">28710774</ArticleId></ArticleIdList></Reference><Reference><Citation>DeLano WL. PyMOL: an open-source molecular graphics tool. CCP4 Newsl Protein Crystallogr. 2002;40:82–92.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>